BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Stanciu GD, Rusu RN, Bild V, Filipiuc LE, Tamba BI, Ababei DC. Systemic Actions of SGLT2 Inhibition on Chronic mTOR Activation as a Shared Pathogenic Mechanism between Alzheimer's Disease and Diabetes. Biomedicines 2021;9:576. [PMID: 34069618 DOI: 10.3390/biomedicines9050576] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 4.5] [Reference Citation Analysis]
Number Citing Articles
1 Qu Y, Ding M, Gu C, Zhang L, Zhen R, Chen J, Hu B, An H. Acteoside and ursolic acid synergistically protects H 2 O 2 -induced neurotrosis by regulation of AKT/mTOR signalling: from network pharmacology to experimental validation. Pharmaceutical Biology 2022;60:1751-61. [DOI: 10.1080/13880209.2022.2098344] [Reference Citation Analysis]
2 Lu Y, Wu H, Zhu T, Li X, Zuo J, Hasan AA, Reichetzeder C, Delic D, Yard B, Klein T, Krämer BK, Zhang Z, Wang X, Yin L, Dai Y, Zheng Z, Hocher B. Empagliflozin reduces kidney fibrosis and improves kidney function by alternative macrophage activation in rats with 5/6-nephrectomy. Biomedicine & Pharmacotherapy 2022;156:113947. [DOI: 10.1016/j.biopha.2022.113947] [Reference Citation Analysis]
3 Stanciu GD, Ababei DC, Rusu RN, Bild V, Tamba BI. Exploring the Involvement of the Amyloid Precursor Protein A673T Mutation against Amyloid Pathology and Alzheimer's Disease in Relation to Therapeutic Editing Tools. Pharmaceutics 2022;14:1270. [PMID: 35745842 DOI: 10.3390/pharmaceutics14061270] [Reference Citation Analysis]
4 Vasincu A, Rusu R, Ababei D, Larion M, Bild W, Stanciu GD, Solcan C, Bild V. Endocannabinoid Modulation in Neurodegenerative Diseases: In Pursuit of Certainty. Biology 2022;11:440. [DOI: 10.3390/biology11030440] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
5 Kamal FZ, Stanciu GD, Lefter R, Cotea VV, Niculaua M, Ababei DC, Ciobica A, Ech-chahad A. Chemical Composition and Antioxidant Activity of Ammi visnaga L. Essential Oil. Antioxidants 2022;11:347. [DOI: 10.3390/antiox11020347] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
6 Rizzo MR, Di Meo I, Polito R, Auriemma MC, Gambardella A, di Mauro G, Capuano A, Paolisso G. Cognitive impairment and type 2 diabetes mellitus: Focus of SGLT2 inhibitors treatment. Pharmacol Res 2022;176:106062. [PMID: 35017046 DOI: 10.1016/j.phrs.2022.106062] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
7 Katsenos AP, Davri AS, Simos YV, Nikas IP, Bekiari C, Paschou SA, Peschos D, Konitsiotis S, Vezyraki P, Tsamis KI. New treatment approaches for Alzheimer's disease: preclinical studies and clinical trials centered on antidiabetic drugs. Expert Opin Investig Drugs 2022;:1-19. [PMID: 34941464 DOI: 10.1080/13543784.2022.2022122] [Reference Citation Analysis]
8 Pawlos A, Broncel M, Woźniak E, Gorzelak-Pabiś P. Neuroprotective Effect of SGLT2 Inhibitors. Molecules 2021;26:7213. [PMID: 34885795 DOI: 10.3390/molecules26237213] [Cited by in Crossref: 15] [Cited by in F6Publishing: 20] [Article Influence: 7.5] [Reference Citation Analysis]
9 Filipiuc LE, Ababei DC, Alexa-Stratulat T, Pricope CV, Bild V, Stefanescu R, Stanciu GD, Tamba BI. Major Phytocannabinoids and Their Related Compounds: Should We Only Search for Drugs That Act on Cannabinoid Receptors? Pharmaceutics 2021;13:1823. [PMID: 34834237 DOI: 10.3390/pharmaceutics13111823] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 5.5] [Reference Citation Analysis]